Ginsenoside‐Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Ginsenosides are the main constituents for the pharmacological effects of Panax ginseng. Such effects of ginsenosides including cardioprotective and anti‐platelet activities have shown stability and bioavailability limitations. However, information on the anti‐platelet activity of ginsenoside‐Rp1 (G‐Rp1), a stable derivative of ginsenoside‐Rg3, is scarce. We examined the ability of G‐Rp1 to modulate agonist‐induced platelet activation. EXPERIMENTAL APPROACH: G‐Rp1 in vitro and ex vivo effects on agonist‐induced platelet‐aggregation, granule‐secretion, [Ca 2+]i mobilization, integrin‐α IIb β 3 activation were examined. Vasodilator‐stimulated phosphoprotein (VASP) and MAPK expressions and levels of tyrosine phosphorylation of the glycoprotein VI (GPVI) signalling pathway components were also studied. G‐Rp1 effects on arteriovenous shunt thrombus formation in rats or tail bleeding time and ex vivo coagulation time in mice were determined. KEY RESULT: G‐Rp1 markedly inhibited platelet aggregation induced by collagen, thrombin or ADP. While G‐Rp1 elevated cAMP levels, it dose‐dependently suppressed collagen‐induced ATP‐release, thromboxane secretion, p‐selectin expression, [Ca 2+]i mobilization and α IIb β 3 activation and attenuated p38 MAPK and ERK2 activation. Furthermore, G‐Rp1 inhibited tyrosine phosphorylation of multiple components (Fyn, Lyn, Syk, LAT, PI3K and PLCγ2) of the GPVI signalling pathway. G‐Rp1 inhibited in vivo thrombus formation and ex vivo platelet aggregation and ATP secretion without affecting tail bleeding time and coagulation time, respectively. CONCLUSION AND IMPLICATIONS: G‐Rp1 inhibits collagen‐induced platelet activation and thrombus formation through modulation of early GPVI signalling events, and this effect involves VASP stimulation, and ERK2 and p38‐MAPK inhibition. These data suggest that G‐Rp1 may have therapeutic potential for the treatment of cardiovascular diseases involving aberrant platelet activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926 · cited 2×
“…activation triggered by pathophysiological factors can lead to the development and progression of cardiovascular disorders such as thrombosis (Furie and Furie, 2008), atherosclerosis (Huo et al., 2003), hypertension (Perros et al., 2008) and inflammation (Gawaz et al., 2005; Zarbock et al.,…”
BackgroundGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Activation of Platelet Function Through G Protein–Coupled Receptors
Offermanns, S. (2006) · Circulation Research · doi:10.1161/01.res.0000251742.71301.16 · Cited by 725 · cited 1×
“In addition, since TXA2 by acting as a positive-feedback mediator amplifies the initial signals to ensure the rapid activation and recruitment of platelets into a growing thrombus (Offermanns, 2006); we examined the effect of G-Rp1 on its secretion.”
Background
Cited by
Ben‐Arye, E., Samuels, N., Goldstein, L. H., Mutafoglu, K., Omran, S., Schiff, E., Charalambous, H., Dweikat, T., Ghrayeb, I., Bar‐Sela, G., et al. (2016) · Cancer · doi:10.1002/cncr.29796 · Cited by 158
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundNatural Products with Antiplatelet Action
Hirsch, G. E., Nazario Viecili, P. R., de Almeida, A. S., Nascimento, S., Porto, F. G., Otero, J., Schmidt, A., da Silva, B., Parisi, M. M., & Klafke, J. Z. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666161123151611 · Cited by 57
Medicinal Plants with Antiplatelet Activity
El Haouari, M., & Rosado, J. A. (2016) · Phytotherapy Research · doi:10.1002/ptr.5619 · Cited by 54
“The antiplatelet effect of ginsenoside-Rp1 implies a modulation of the GPVI signaling pathway events including VASP stimulation and ERK2 and p38 (MAPK) inhibition (Endale et al., 2012).”
BackgroundAnthocyanin Cyanidin-3-Glucoside Attenuates Platelet Granule Release in Mice Fed High-Fat Diets
ZHOU, F.-H., DENG, X.-J., CHEN, Y.-Q., YA, F.-L., ZHANG, X.-D., SONG, F., LI, D., & YANG, Y. (2017) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.63.237 · Cited by 23
Metadata
- Authors
- Endale, M., Lee, W., Kamruzzaman, S., Kim, S., Park, J., Park, M., Park, T., Park, H., Cho, J., & Rhee, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-08-03
- Volume
- 167
- Issue
- 1
- Pages
- 109-127
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1586532694
- Cited by
- 90
- References
- 4
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ginsenoside‐Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.01967.x
- The paper
- Endale, M., Lee, W., Kamruzzaman, S., Kim, S., Park, J., Park, M., Park, T., Park, H., Cho, J., & Rhee, M. (2012). Ginsenoside‐Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.01967.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.